Overview

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Status:
Active, not recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Antibodies